Niagen Bioscience (NAGE) Amortization of Deferred Charges (2019)

Niagen Bioscience (NAGE) has reported Amortization of Deferred Charges for 5 consecutive years, with $164000.0 the latest figure, recorded in Q3 2024.

• In Q3 2024, Amortization of Deferred Charges fell 6.82% year-over-year to $164000.0; the TTM figure through Sep 2024 stood at $658000.0 (down 7.45% YoY), while the FY2023 annual figure was $677000.0, down 18.34% from the prior year.
• Amortization of Deferred Charges grew to $164000.0 in Q3 2024 per NAGE's latest filing, from $163000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $299000.0 in Q1 2022 and bottomed at $126000.0 in Q1 2021.
• Historically, Amortization of Deferred Charges has averaged $167866.7 across 4 years, with a median of $169000.0 in 2022.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges soared 137.3% — and 2023, when it plunged 42.81%.
• Niagen Bioscience's Amortization of Deferred Charges stood at $126000.0 in 2021, then jumped by 51.59% to $191000.0 in 2022, then dropped by 17.8% to $157000.0 in 2023, then grew by 4.46% to $164000.0 in 2024.
• Business Quant data shows NAGE's Amortization of Deferred Charges at $164000.0 in Q3 2024, $163000.0 in Q2 2024, and $174000.0 in Q1 2024.